Quatrx Pharmaceuticals Announces New Management Appointments
Quatrx Pharmaceuticals Announces New Management Appointments
Quatrx Pharmaceuticals Announces New Management Appointments
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
2/<br />
About QuatRx<br />
QuatRx <strong>Pharmaceuticals</strong> Company is focused on discovering, licensing, developing and<br />
commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic<br />
areas. QuatRx currently has four product candidates in clinical development. QuatRx’s two<br />
lead compounds treat hormone deficiencies that result from aging in women and men.<br />
Ophena is in Phase III development initially for the treatment of vaginal atrophy, a<br />
common problem associated with estrogen deficiency in post-menopausal women.<br />
Fispemifene, a treatment for testosterone deficiency, is in Phase II clinical testing. QuatRx<br />
also has QRX-431, a product candidate for the treatment of elevated cholesterol levels, and<br />
Asord, a topical product candidate for the treatment of mild to moderate psoriasis, which<br />
has completed a Phase IIb clinical trial.<br />
# # #
Change language